Originally developed to treat type 2 diabetes, GLP-1 receptor agonists have rapidly become a cornerstone of obesity management, fundamentally altering the trajectory of U.S. healthcare. Their surging popularity is driving shifts in clinical practice, insurance coverage dynamics, and public health policy nationwide.
Also Read
- FDA Approves Kenvue’s TYLENOL with Naproxen: First OTC Combination for Combined Pain Relief
- Sessions Court Dismisses NCCIA Bid to Shift Falak Javed Trial to Prison
- Fuel Price Surge Drives Food Costs to Record Highs in Rawalpindi
- Archaeological Discovery: Ancient Statues Unearthed at Karachi’s Lea Market